@indyhematology.bsky.social
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
DRIVE Initiative | Achieving Clinical Trial Excellence — Indy Hematology Education
Learn about DRIVE Initiative's efforts to promote representative enrollment and excellence in hematology and oncology clinical trials.
www.indyhematology.org
October 24, 2025 at 5:02 PM
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 0*. Studies receiving a score of 0* separate race and ethnicity
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to hear about DRIVE Scores and drug generalizability for FDA Approvals
(www.fda.gov/drugs/resour...)
This study received a DRIVE Score of 0*. Studies receiving a score of 0* separate race and ethnicity
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to hear about DRIVE Scores and drug generalizability for FDA Approvals
(www.fda.gov/drugs/resour...)
FDA approves lurbinectedin in combination with atezolizumab
On October 2, 2025, the Food and Drug Administration approved lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs.
www.fda.gov
October 6, 2025 at 7:28 PM
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 0*. Studies receiving a score of 0* separate race and ethnicity
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to hear about DRIVE Scores and drug generalizability for FDA Approvals
(www.fda.gov/drugs/resour...)
This study received a DRIVE Score of 0*. Studies receiving a score of 0* separate race and ethnicity
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to hear about DRIVE Scores and drug generalizability for FDA Approvals
(www.fda.gov/drugs/resour...)
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 1, NOT achieving clinical trial excellence
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
This study received a DRIVE Score of 1, NOT achieving clinical trial excellence
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
FDA approves imlunestrant
On September 25, 2025, the Food and Drug Administration approved imlunestrant (Inluriyo, Eli Lilly and Company).
www.fda.gov
September 25, 2025 at 7:28 PM
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 1, NOT achieving clinical trial excellence
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
This study received a DRIVE Score of 1, NOT achieving clinical trial excellence
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
🚨NEW SERIES🚨
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
FDA approves pembrolizumab and berahyaluronidase alfa-pmph
On September 19, 2025, the Food and Drug Administration approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for subcutaneous injection
www.fda.gov
September 22, 2025 at 5:46 PM
🚨NEW SERIES🚨
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
FDA Alerts DRIVE Score 🚗
This study received a DRIVE Score of 3, achieving clinical trial excellence!👏
Read more about DRIVE here (www.indyhematology.org/drive)
Stay tuned to learn about DRIVE Scores and the generalizability for all FDA Approvals
(www.fda.gov/drugs/resour...)
🚨 Spotlight Speaker Alert! 🚨
Indy Hematology Education is proud to present Dr. Ruemu Birhiray, our President & CEO, as a spotlight speaker 🎤 at #DRIVE2025! #CancerResearch
📅 March 7, 2025 | 📍 Westin, Indianapolis
🔗 Register now: indyhematologyreview.com/register/
Indy Hematology Education is proud to present Dr. Ruemu Birhiray, our President & CEO, as a spotlight speaker 🎤 at #DRIVE2025! #CancerResearch
📅 March 7, 2025 | 📍 Westin, Indianapolis
🔗 Register now: indyhematologyreview.com/register/
February 23, 2025 at 6:56 PM
🚨 Spotlight Speaker Alert! 🚨
Indy Hematology Education is proud to present Dr. Ruemu Birhiray, our President & CEO, as a spotlight speaker 🎤 at #DRIVE2025! #CancerResearch
📅 March 7, 2025 | 📍 Westin, Indianapolis
🔗 Register now: indyhematologyreview.com/register/
Indy Hematology Education is proud to present Dr. Ruemu Birhiray, our President & CEO, as a spotlight speaker 🎤 at #DRIVE2025! #CancerResearch
📅 March 7, 2025 | 📍 Westin, Indianapolis
🔗 Register now: indyhematologyreview.com/register/
🚗💨 Get ready to D.R.I.V.E. real change in clinical research! Let’s build a future where ALL patients are represented and included. Who’s in? 🙌
📍 Westin, Indianapolis
📅 March 7
🔗 Register now: indyhematologyreview.com/register/
#DRIVE2025 #ClinicalTrials #DiversityInResearch
📍 Westin, Indianapolis
📅 March 7
🔗 Register now: indyhematologyreview.com/register/
#DRIVE2025 #ClinicalTrials #DiversityInResearch
February 21, 2025 at 4:59 PM
🚗💨 Get ready to D.R.I.V.E. real change in clinical research! Let’s build a future where ALL patients are represented and included. Who’s in? 🙌
📍 Westin, Indianapolis
📅 March 7
🔗 Register now: indyhematologyreview.com/register/
#DRIVE2025 #ClinicalTrials #DiversityInResearch
📍 Westin, Indianapolis
📅 March 7
🔗 Register now: indyhematologyreview.com/register/
#DRIVE2025 #ClinicalTrials #DiversityInResearch
🧬Join leading researchers and healthcare professionals as we explore the latest clinical therapies in lymphoma diagnosis and treatment! Don’t miss this chance to connect with experts and stay ahead in the field!
📍Westin Chicago River North
Be part of the conversation. Be part of the cure
#IUCLS2025
📍Westin Chicago River North
Be part of the conversation. Be part of the cure
#IUCLS2025
February 13, 2025 at 8:02 PM
🧬Join leading researchers and healthcare professionals as we explore the latest clinical therapies in lymphoma diagnosis and treatment! Don’t miss this chance to connect with experts and stay ahead in the field!
📍Westin Chicago River North
Be part of the conversation. Be part of the cure
#IUCLS2025
📍Westin Chicago River North
Be part of the conversation. Be part of the cure
#IUCLS2025